News & events

genOway Shanghai at the Chinese Biopharmaceutical Association meeting 2024

5th Annual STING & TLR-Targeted Therapies Summit, San Diego, CA, June 19-20, 2024

Another technological achievement for genOway's humanized ICP (immune checkpoint) models, used successfully by Curadev Pharma in the preclinical trials of its drug candidate CRD3874 for the treatment of advanced/metastatic solid cancers

Sigma-Aldrich and genOway expand their CRISPR/Cas9 strategic alliance

genOway grants the leading UK academic research funder a non-exclusive license for CRISPR/Cas9 technology

ERS Genomics and genOway enter CRISPR/Cas9 agreement

After the United States, the European Patent Office delivers the first European patent for the SMASh technology — and genOway has acquired an exclusive license

genOway obtains €2,3M from the European Union and the Auvergne-Rhône-Alpes Region to develop humanized immune checkpoint models

genOway and Cyagen have joined forces to form a long-term strategic partnership in the Asia-Pacific region

genOway and Merck strengthen CRISPR/Cas9 strategic alliance by extending their partnership to all animal cell models

genOway announces the acquisition of Axenis to create the largest offer of preclinical models in the Immuno-oncology and Immuno-inflammation space